News about Global Pharma

AbbVie Gets Positive CHMP Opinion for Mirvetuximab Soravtansine

AbbVie has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine (ELAHERE).

Global Pharma | 21/09/2024 | By Aishwarya |  588

Lupin Gets FDA Approval for Bumetanide Injection

Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multiple-Dose Vials are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

Global Pharma | 20/09/2024 | By Aishwarya |  624

Lifecore Biomedical's Isolator Filler Now GMP-Ready and Operational

Lifecore is now positioned to offer existing and future customers the speed and aseptic isolation benefits of this state-of-the-art technology for fill/finish services for prefilled syringes, vials, and cartridges.

Global Pharma | 20/09/2024 | By Aishwarya |  380

Aurobindo to Fully Acquire GLS Pharma for INR 22.5 Crore

The company entered into a binding agreement with GLS Pharma Ltd. and its promoters for the acquisition of the remaining 5,90,361 equity shares of INR 10 each amounting to a 49 percent stake for a purchase consideration of INR 22.5 crore.

Global Pharma | 19/09/2024 | By Aishwarya |  770

Seran Bioscience Announces USD 200 Million Strategic Growth Transaction

The new facility will be completed in 2026 and will support oral, pulmonary, and nasal delivery modalities with commercial-scale particle engineering solutions, including spray drying, hot melt extrusion, nano-milling, and fluid-bed manufacturing, as well as comprehensive finished dose capabilities.

Global Pharma | 18/09/2024 | By Aishwarya |  517

Sanofi Begins Shipping BEYFORTUS in US

Sanofi has started shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its vaccines for children program.

Global Pharma | 18/09/2024 | By Aishwarya |  476

Merck Signs MoU with Siemens to Accelerate Digital Transformation Technology

The MoU makes Siemens a preferred global supplier and strategic partner for Smartfacturing technologies, paving the way for transformative projects across Merck's three business sectors.

Global Pharma | 18/09/2024 | By Aishwarya |  647

Piramal Pharma Gets SBTi Approval for its GHG Emission Reduction Targets

Piramal Pharma Ltd. has committed to reduce absolute scope 1 and 2 GHG emissions 42 percent by FY2030 from a FY2022 base year.

Global Pharma | 17/09/2024 | By Aishwarya |  525

Strides Secures FDA Approval for Fluoxetine Tabs

With the approval of the Fluoxetine Tabs 60 mg strength, the company is now positioned to offer a complete portfolio of Fluoxetine across Capsules and Tablets in 10 mg, 20 mg, and 60 mg strengths.

Global Pharma | 17/09/2024 | By Aishwarya |  530

Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis

Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.

Global Pharma | 17/09/2024 | By Aishwarya |  744